

1 **Performance of Immunological Assays for Universal and Differential Diagnosis of**
2 **HTLV-1/2 Infection in Candidates for Blood Donations from the Brazilian Amazon**

3
4 Felipe Araujo Santos^{1,2}; Cláudio Lucas Santos Catão^{1,2}; Júlia Pereira Martins^{3,4}; Uzamôr
5 Henrique Soares Pessoa²; Isabelle Vasconcelos Sousa^{2,5}; Jean Silva Melo^{6,7}; Gláucia
6 Lima Souza^{1,2}; Nilberto Dias Araújo^{1,2,6}; Fábio Magalhães-Gama^{2,3,4}; Cláudia Maria de
7 Moura Abraham²; Emmily Myrella Vasconcelos Mourão⁷; Vanessa Peruhype-Magalhães⁴;
8 Jordana Graziela Alves Coelho-dos-Reis^{4,8}; Andréa Teixeira-Carvalho^{3,4}; Antonio
9 Carlos Rosário Vallinoto^{9,10}; Gemilson Soares Pontes^{1,6,7}; Márcio Sobreira Silva Araújo^{3,4};
10 Olindo Assis Martins-Filho^{1,3,4} & Allyson Guimarães da Costa^{1,2,5,6*}

11
12 ¹Programa de Pós-Graduação em Ciências Aplicadas à Hematologia, Universidade do Estado
13 do Amazonas (UEA), Manaus, Brazil;

14 ²Diretoria de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do
15 Amazonas (HEMOAM), Manaus, Brazil;

16 ³Programa de Pós-Graduação em Ciências da Saúde, Instituto René Rachou - Fundação
17 Oswaldo Cruz (FIOCRUZ) Minas, Belo Horizonte, Brazil;

18 ⁴Grupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou - FIOCRUZ Minas,
19 Belo Horizonte, Brazil;

20 ⁵Programa de Pós-Graduação em Enfermagem, Escola de Enfermagem de Manaus,
21 Universidade Federal do Amazonas (UFAM), Manaus, Brazil;

22 ⁶Programa de Pós-Graduação em Imunologia Básica e Aplicada, Instituto de Ciências Biológicas,
23 UFAM, Manaus, Brazil;

24 ⁷Laboratório de Virologia, Instituto Nacional de Pesquisa da Amazônia (INPA), Manaus, Brasil;

25 ⁸Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas
26 Gerais (UFMG); Belo Horizonte, Brazil;

27 ⁹Programa de Pós-graduação em Biologia de Agentes infecciosos e Parasitários, Universidade
28 Federal do Pará (UFPA), Belém, Brasil;

29 ¹⁰Laboratório de Virologia, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém,
30 Brazil.

31
32 ***Correspondence:** Allyson Guimarães da Costa, Rua Terezina, 495, Adrianópolis, Manaus,
33 Amazonas, Brazil, CEP: 69057-070. Phone: +55 92 98153-5233, E-mail:
34 allyson.gui.costa@gmail.com
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 ABSTRACT

36 The present study compares the ability of distinct immunological assays
37 (chemiluminescence immunoassay-CLIA, western blot-WB and flow cytometry-FC-
38 Simplex and Duplex) to detect anti-HTLV antibodies in candidates for blood donations at
39 the Amazonas State Blood Center (Brazil) between January 2018 and December 2022.
40 Overall, 257,942 samples from candidates for blood donations were screened using
41 CLIA, which led to 0.15% seropositivity for HTLV (409 samples). A total of 151 candidates
42 for blood donations were enrolled for retesting with CLIA followed by additional testing
43 using WB and FC-Simplex and Duplex analysis. Our results demonstrated that 62%
44 (93/151), 20% (30/151) and 17% (26/151) of the samples presented positive results with
45 retesting using CLIA, WB and FC-Simplex analysis, respectively. Additional analysis of
46 the CLIA, WB and FC-Simplex results revealed an overall agreement of 56% for CLIA
47 and WB (22 co-negative; 30 co-positive samples), 48% for CLIA and FC-Simplex (21 co-
48 negative; 24 co-positive samples) and 80% for WB and FC-Simplex (51 co-negative; 23
49 co-positive samples). Considering the WB as the reference standard for the diagnosis of
50 infection with HTLV-1/2, we observed that the CLIA results of ≤ 3.0 RLU and > 10.0 RLU
51 in the retest can be used to define a negative or positive result, respectively, and could be
52 used as new specific cut-off values. The overall agreement between WB and FC-Duplex
53 for accomplishing the differential diagnosis was evaluated and demonstrated 100%
54 correspondence for the diagnosis of HTLV-1 (15/15) and HTLV-2 (7/7). Our findings
55 demonstrate that gaps in the diagnosis of infection with HTLV-1/2 could be overcome by
56 the simultaneous use of distinct immunological assays during retesting of candidates for
57 blood donations.

58

59 **Keywords:** HTLV-1/2, universal diagnosis, differential diagnosis, sensitivity, specificity.

60

61 1. INTRODUCTION

62 Discovered in 1980, human T-lymphotropic virus (HTLV) is an oncogenic retrovirus
63 that has 4 types (HTLV-1, HTLV-2, HTLV-3 and HTLV-4). HTLV-1 and HTLV-2 are
64 viruses that are considered to be of medical importance and are related to adult T-cell
65 leukemia/lymphoma (ATLL), neurodegenerative diseases such as HTLV-1 associated
66 myelopathy/tropical spastic paraparesis (HAM/TSP) and hairy cell infections [1–3]. It is
67 estimated that 3 to 5% of HTLV-1 infections may evolve into these pathologies, while

68 HTLV-2 infection still needs to be better characterized regarding its relationship with these
69 clinical diseases [4–10].

70 Transmission of the virus in humans can occur through sexual contact, blood
71 transfusions, transplants with contaminated organs, breastfeeding of newborns and
72 accidents with or sharing of contaminated sharp instruments [7,11–13]. HTLV-1/2
73 infections are estimated to affect approximately 10 to 20 million people worldwide and
74 depending on the region, prevalence can range between 5% and 27% [1,14]. Areas of
75 Japan, the Caribbean Islands, Africa, South America, some regions of Romania and the
76 Middle East are endemic for HTLV-1, while HTLV-2 is found in pygmies in Central
77 America, African countries, and indigenous populations of the Americas [1,2,15].

78 In Brazil, the first cases of HTLV were detected in 1986, in a community of
79 Japanese descendants in Mato Grosso do Sul [16]. Subsequently, the detection of the
80 virus in different Brazilian regions and states was described, with a greater number of
81 cases in the states of Bahia, Maranhão and Pará, although the infection is considered
82 endemic and has a heterogeneous distribution [17,18]. In the northern region of Brazil,
83 reports have shown a high prevalence of HTLV-1/2 infection in blood donors from the
84 states of Amapá (0.71%) and Pará (0.91%), although in Amazonas the number of cases
85 is considered low (0.13%) [19–21].

86 Due to their higher sensitivity, the screening of patients or blood donors for HTLV-
87 1/2 is initially carried out with the enzyme immunosorbent assay (ELISA),
88 chemiluminescent immunoassay (CLIA) and the particle agglutination assay (PA).
89 Subsequently, confirmatory assays are performed using western blot (WB), line
90 immunoassay (INNO-LIA) and quantitative real-time polymerase chain reaction (qPCR).
91 These assays have a high specificity for detecting specific antibodies for different HTLV
92 antigens, as well as molecular detection of the genetic material of the provirus [22,23]. In
93 addition to these tests, a new method for screening and differential diagnosis of HTLV-
94 1/2 infection based on the flow cytometry technique presented promising results for
95 screening with the FC-Simplex IgG1 (HTLV) and differential diagnosis for HTLV-1/2
96 infection with the FC-Duplex IgG1 (HTLV-1/2) assay [24–26].

97 WB is considered to be the reference standard for the detection and diagnosis of
98 HTLV-1/2 infection, although it has limitations regarding seroconversion in newly infected
99 individuals, in addition to high costs due to the limited availability of tests [27–29].
100 Moreover, the difficulty of automating these assays is noted, with the use of CLIA being

101 proposed for blood centers since it has excellent sensitivity and the ability to track
102 infection, despite false-positive results [28,30–32]. Thus, a study was carried out in order
103 to compare the performance of distinct immunological assays (CLIA, WB, FC-Simplex
104 and Duplex) to detect anti-HTLV antibodies in candidates for blood donations at the
105 Amazonas State Blood Center (Brazil).

106

107 **2. MATERIALS AND METHODS**

108

109 **2.1 Study design**

110 A longitudinal study was carried out with blood donor candidates from the state of
111 Amazonas, Brazil, who were evaluated at the Fundação Hospitalar de Hematologia e
112 Hemoterapia do Amazonas (HEMOAM) and who had a positive result for HTLV-1/2
113 infection via the CLIA in the period from January 2018 to December 2022. The state of
114 Amazonas has a low prevalence of HTLV-1/2 infection, which was previously estimated
115 to be 0.13% [20].

116 **2.2 Ethical statement**

117 Ethical approval for the study was obtained from the Research Ethics Committee
118 at the HEMOAM Foundation (approval number #5.348.608, CAEE:
119 57153922.5.0000.0009). All procedures are in accordance with Resolution 466/12 of the
120 Brazilian Ministry of Health and the Declaration of Helsinki. All the participants read and
121 signed the informed consent form before enrollment.

122 **2.3 Characteristics of the study population**

123 Individuals aged 18 years or older who were seropositive for anti-HTLV-1/2 in the
124 CLIA screening test were interviewed. Those who accepted and signed the informed
125 consent form (ICF) were subjected to a CLIA retest, in addition to the WB, FC-Simplex
126 and FC-Duplex assays. The results of immunological assays were not used for medical
127 decisions regarding diagnosis and treatment. Furthermore, participants who tested
128 positive for HTLV-1 or HTLV-2 infection via the WB assay were considered to have a
129 defined diagnosis.

130

131 **2.4 Acquisition of clinical and laboratory data**

132 Sociodemographic and clinical information was collected through a questionnaire
133 and from the records of the Serology Laboratory using the HEMOSYS system.
134 HEMOSYS data were updated at the time of applying the ICF.

135 **2.5 Collection and processing of biological samples**

136 Venous blood for immunological assays was collected using a vacuum system in
137 tubes with EDTA and separating gel (BD Vacutainer EDTA® K2 and BD gel SST®
138 Advance II). Subsequently, the biological samples were centrifuged, and aliquots of ±700
139 uL were prepared and frozen at -80 °C until the CLIA, WB, FC-Simplex and FC-Duplex
140 assays were carried out.

141 **2.6 Chemiluminescence assay (CLIA)**

142 The chemiluminescence assay (CLIA) was carried out in the serology sector of the
143 HEMOAM Foundation as a screening and retesting step to detect donors that were
144 positive for HTLV-1/2 infection. The procedure consists of a two-step immunoassay for
145 the qualitative detection of antibodies to HTLV-1 and HTLV-2 in serum, using the Alinity
146 s rHTLV-I/II kit (Abbott®). The immunoassay is performed with a closed system and
147 chemiluminescent microparticle technology (Alinity i-SCM 02 Ai01767, Abbott®). The
148 tests were carried out following the guidelines of the kit and equipment's manufacturers,
149 with results expressed in relative light units (RLU).

150 **2.7 Western blot assay**

151 The western blot (WB) assay was performed with the HTLV blot 2.4 kit (MP
152 diagnostics®), following the guidelines of the manufacturer of the kit. The WB is qualitative
153 enzyme immunoassay uses for detection of the antibodies to HTLV-1/2 in human serum
154 and is used as a confirmatory step methodology that is capable of detecting and
155 distinguishing virus types 1 and 2, generating positive, negative or indeterminate results.

156 **2.8 Flow cytometry assay**

157 The FC-Simplex IgG1 (HTLV) assay was developed as a qualitative support
158 methodology for the detection of infections with HTLV, and uses commercial cells infected
159 with the virus [24,26]. This technology uses a system for detecting IgG1 antibodies on a
160 competitive immunofluorescence platform using flow cytometry, with MT-2 cells as
161 antigenic support. The assay aims to select positive samples, but without distinguishing
162 between viral types, and functions as a screening step for FC-Duplex IgG1 HTLV.

163 Subsequently, the FC-Duplex IgG1 (HTLV-1/2) assay was performed as a supporting
164 assay for the differential diagnosis of HTLV-1/2 infection, using commercial cells infected
165 with the viruses [25]. The assay uses a system for detecting IgG1 antibodies in a
166 competitive immunofluorescence platform using flow cytometry, using MT-2 and MoT cell
167 lines stained with the fluorochrome Alexa Fluor 647 (AF647) as antigenic support. In both
168 tests, the results are expressed as a percentage of positive fluorescent cells (PPFC),
169 which were obtained with the detection system after acquiring the samples in the
170 FACSCalibur cytometer and analyzing the MFI with the FlowJo software (v10.1).

171 2.9 Statistical analysis

172 Prisma GraphPad Software version v.8.1 (GraphPad Prism, San Diego, CA, USA)
173 was used to create graphs and perform the statistical analyses. The Shapiro-Wilk test
174 was used to verify the distribution and normality of the variables, which showed a non-
175 parametric distribution. Comparison of RLU and PPFC data was performed using the
176 Mann-Whitney test. The level of statistical significance in all the analyses was defined as
177 $p < 0.05$.

178

179 3. RESULTS

180 During the study period (Jan, 2018 to Dec, 2022), 409 samples from the 257,942
181 candidates for blood donations (0.15%) presented a positive result for anti-HTLV-1/2 IgG
182 during screening using the CLIA, which was carried out at HEMOAM. The median
183 reactivity of the positive samples was 1.79 RLU. **Table 1** summarizes the demographical
184 and laboratorial records of the candidates for blood donations with positive results for
185 HTLV-1/2 during serological screening using the CLIA.

186 After the initial screening using the CLIA, donor candidates with positive results
187 were invited to provide a new blood sample for retesting using the CLIA to confirm
188 seropositivity for HTLV-1/2 antibodies (**Figure 1**). A total of 151 donor candidates agreed
189 to participate in the retesting using the CLIA. Data analysis revealed that 93 out of the
190 151 samples (62%) exhibited positive results in the retest with the CLIA, with a median
191 reactivity of 2.50 RLU (**Figure 1a**). Comparative analysis between positive CLIA results
192 obtained during screening and the retest presented a high correlation “r” score (0.89,
193 $p < 0.0001$) (**Figure 1b**).

194 The 93 samples were additionally tested using two other immunological tests (WB
195 and FC-Simplex). The results demonstrated that 30 samples (20%) presented positive
196 results in the WB and 26 (17%) in the FC-Simplex (**Supplementary Table 1**). Additional
197 analysis of the scattering distribution of the CLIA results of the retesting allowed the
198 identification of three clusters, which were further classified as: low RLU (1.0-1.3),
199 intermediate RLU (>1.3-3.0) and high RLU (>3.0-400), comprising 22%, 35% and 43% of
200 tested samples, respectively. Data from the WB were also classified into three categories,
201 considering the band profiles, as: negative (no reactivity or reactivity to proteins other
202 than p19 or p24), indeterminate (reactivity to HTLV specific bands that do not meet the
203 criteria for HTLV-1/2 seropositivity) and positive results (reactivity to p19, GD21 and
204 rgp46-I for HTLV-1 or reactivity to p24, GD21 and rgp46-II for HTLV-2), comprising 57%,
205 11% and 32% of the tested samples, respectively. The results of FC-Simplex analysis
206 were subsequently classified into two categories according to the magnitude of the PFFC
207 results as: negative (PFFC \leq 20%) and positive (>20%) comprising 74% and 26% of the
208 tested samples, respectively (**Figure 2a**).

209 For further analysis of the results obtained during the retesting, the data from the
210 CLIA, WB and FC-Simplex were analyzed considering the distinct categories of results
211 obtained in each assay (low, intermediate and high - CLIA, positive, negative and
212 indeterminate - WB, negative and positive - FC), as previously proposed in the **Figure**
213 **2a**. Comparative analysis of the CLIA and WB revealed an overall agreement of 56% (22
214 co-negative and 30 co-positive samples), while the CLIA and FC-Simplex yielded 48% of
215 agreement (21 co-negative and 24 co-positive samples). Comparison between the WB
216 and FC-Simplex demonstrated higher agreement (80%) with 51 co-negative and 23 co-
217 positive samples (**Figure 2b**).

218 Using the WB as a reference method for confirmatory diagnosis of HTLV-1/2
219 infection, our findings demonstrated that any CLIA result of \leq 3.0 RLU should be
220 considered a negative result while a CLIA result of >10.0 RLU should define a positive
221 result.

222 In order to accomplish the differential diagnosis of HTLV-1 and HTLV-2 infection,
223 the WB and the FC-Duplex assay were carried out in parallel batches. The WB results for
224 HTLV-1 from HTLV-2 for differential diagnosis were considered according to the
225 manufacturer instructions and the FC-Duplex results were classified using the criteria
226 previously proposed by Pimenta de Paiva et al. [25]. According to their criteria, the

227 differential diagnosis of HTLV infection using FC-Duplex can be achieved as the Δ PPFC
228 = (MT-2 1:32 - Mot 1:32). Using this criterion, out of 22 of the tested samples, fifteen were
229 classified as HTLV-1 and seven as HTLV-2. Comparative analysis between the WB and
230 FC-Duplex results (criterion 1) demonstrated 100% agreement for HTLV-1 (15/15) and
231 HTLV-2 (7/7) (**Figure 3**). Pimenta de Paiva et al. [25] proposed two additional criteria for
232 differential diagnosis of HTLV infection using FC-Duplex. The use of these criteria did not
233 show outstanding agreement when compared with the WB reference diagnosis [criterion
234 2 (HTLV-1 (15/15), HTLV-2 (4/7) with 3/7 misclassifications); criterion 3 (HTLV-1 (15/15),
235 HTLV-2 (5/7) with 2/7 misclassifications)] (**Supplementary Figures 1 and 2**).

236

237 **4. DISCUSSION**

238 During the 5 years of screening blood donors that were reactive for HTLV-1/2 at
239 the HEMOAM Foundation, we detected 409 individuals who were considered unfit to
240 donate due to reactive serology for the virus when using the CLIA. At the time of the
241 donation attempt, these individuals are flagged in the HEMOSYS system as having
242 pending issues. They are subsequently contacted by the blood center and asked to return
243 for a retest to confirm the diagnosis. This procedure occurs in accordance with guidance
244 of the Brazilian Ministry of Health and Law 17,344, which makes the diagnosis and
245 monitoring of individuals infected with HTLV mandatory, so that they can be treated for
246 their serological condition [22] .

247 During the study period (2018 to 2022), we identified a prevalence of 0.15% of
248 anti-HTLV antibodies (n= 257,942 eligible donors during the study period). We observed
249 a slight increase in this prevalence when we compared it with data from previous surveys
250 carried out in the same region of Brazil, which identified a prevalence of 0.13% (n=87,402)
251 in the period from 2001 to 2003, and 0.14% (n=6,865) in the period from 2008 to 2009
252 when using ELISA. This indicates that the prevalence in the state was generally
253 maintained [20,33]. It is important to consider that the present study presented a longer
254 survey period and covered a greater number of donors, though a similar prevalence was
255 observed. These data demonstrate that Amazonas continues to be one of the states with
256 the lowest prevalence when compared to others in the northern region of Brazil, such as
257 Amapá (0.71%) and Pará (0.91%) [34,35].

258 Despite the low prevalence of HTLV-reactive blood donors in the city of Manaus,
259 new studies must be carried out, especially considering other populations that are not

260 blood donors, such as riverine and indigenous people. Conducting research with other
261 populations would provide complementary data and give a better overview of the
262 prevalence of the HTLV virus in Amazonas. If new surveys are carried out on blood
263 donors, it would be interesting to use the same assay methodologies as in the present
264 study, with the aim of providing a safer comparison, taking into account that ELISA and
265 CLIA may differ in terms of the screening and diagnosis process [30,35,36].

266 In our study, of the 151 individuals resubmitted to the CLIA, 93 (62%) were positive
267 and were selected to undergo confirmatory retests. Using the WB, the main methodology
268 used to confirm the type of HTLV, we identified 30 (20%) positive, 10 (7%) indeterminate
269 and 111 (73%) negative samples. In addition, via the FC-Simplex, 26 (29%) positive and
270 67 (71%) negative samples for HTLV were identified. Indeterminate cases in the WB
271 assay may be associated with the individual's seroconversion period, as well as cross
272 reactions, which make accurate diagnosis of HTLV difficult. Cross-reactivity may be linked
273 to individuals who had a recent *P. falciparum* infection, as studies in endemic areas have
274 shown that infection by the parasite can interfere with the result and is capable of
275 producing false positives in the WB [37]. Noteworthy, the Amazon is considered an
276 endemic area for malaria in the country, with 99% of autochthonous cases, and this could
277 contribute to the number of indeterminate cases observed [35,38].

278 Regarding the comparison of the assays evaluated, when we categorized them
279 into low, intermediate and high RLU (**Figure 2a**) according to the CLIA sensitivity cut-off
280 point, it was identified that the low and intermediate zones were negative in the WB and
281 the FC-Simplex. The CLIA's very low cut-off point is a good factor for using this
282 methodology as a screening test, as has been observed in other studies carried out to
283 verify the application of this assay during screening [30–32,36]. However, false-positive
284 results in immunological assays need to be evaluated and minimized, as this impacts the
285 quality of life of candidates for blood donations with a positive result during screening
286 tests. In our study, we propose that the RLU values currently used in the CLIA need to
287 be revised, and any CLIA results of ≤ 3.0 RLU should be considered negative results
288 while CLIA results of >10.0 RLU would define a positive result. Other studies reinforce
289 these findings and state that the assays need to be revised, and sequential tests can be
290 used, with different methodologies or adjustments in the cutoff values in the CLIA used
291 to screen blood donors in Brazil, thus avoiding the use of confirmatory assays [39–41].

292 Despite the CLIA's weaknesses in relation to the seroconversion period of
293 individuals, in addition to cross-reactivity, the test appears to be efficient in preventing the
294 passage and distribution of blood bags contaminated with the HTLV virus. However, it
295 does not have the same efficiency when used as a diagnostic method for the virus, due
296 to its low agreement (56%) when compared to the WB. On the other hand, the FC-
297 Simplex assay (still in the validation phase) showed better performance (agreement =
298 80%), and can be used to confirm the screening process, before confirming the differential
299 diagnosis with the WB or qPCR [26]. Additionally, we observed that the FC-Duplex, the
300 assay responsible for the viral distinction between HTLV-1 and HTLV-2 as a phase after
301 FC-Simplex, also presented excellent results, with 100% agreement when compared to
302 the WB for the samples analyzed [25,26]. Although these results are promising, we note
303 that only criterion 1 (MT-2 1;32 minus MoT 1;32) was considered satisfactory for
304 agreement with the WB results, whereby 15 (100%) reactive samples were identified for
305 HTLV-1 and 7 (100%) for HTLV-2. This highlights the ability of the FC-Duplex to
306 distinguish other viruses from HTLV, while also being a low cost and accessible assay for
307 blood banks in Brazil [25].

308 It is important to highlight that our study has some limitations. In the initial survey
309 of individuals that were reactive for HTLV, 409 blood donors that were reactive for the
310 virus were identified. However, due to the lack of updating of records in the institution's
311 database, it was not possible to obtain contact with a significant number of individuals,
312 and a large portion did not show interest in returning for a new CLIA, which ended up
313 having a significant impact on the number of participants in the study. In addition, we did
314 not perform the qPCR technique, which would have provided valuable data for
315 comparison with other methodologies, in addition to being useful to elucidate the
316 serological status of the ten samples that were categorized as indeterminate in the WB.
317 Finally, due to the state of Amazonas being an endemic area for malaria, it is important
318 to evaluate possible co-infection in these individuals so as to eliminate possible biases.

319

320 **5. CONCLUSION**

321 Our results demonstrate the low seroprevalence of HTLV among candidates for
322 blood donation in the state of Amazonas. They also demonstrate that levels are lower
323 than those of other states in the northern region of Brazil. We also showed that the CLIA
324 is highly effective in the screening stage of candidates for blood donations, although it

325 presents many false-positive results and the need for confirmatory tests. In addition, FC-
326 simplex and FC-Duplex were able to identify reactive samples, and could make the
327 distinction between HTLV-1/2. It is therefore a promising methodology for confirming
328 HTLV infection when compared with WB, which is the reference assay. Furthermore, our
329 findings indicate that gaps in the diagnosis of HTLV-1/2 infection could be overcome by
330 the simultaneous use of distinct immunological assays during retesting of candidates for
331 blood donations.

332

333 **DATA AVAILABILITY STATEMENT**

334 The original contributions presented in the study are included in the article/supplementary
335 material, further inquiries can be directed to the corresponding author/s.

336

337 **ETHICS STATEMENT**

338 The present study was submitted to and approved by the Ethical Committee at Fundação
339 HEMOAM, under the protocol registration number #739.563/2014. The participants read
340 and signed the informed consent form prior to inclusion in the study. The study fulfills the
341 principles of the Declaration of Helsinki and resolution 466/2012 of the Brazilian National
342 Health Council for research involving human participants.

343

344 **CONFLICT OF INTEREST**

345 The authors declare that the research was conducted in the absence of any commercial
346 or financial relationships that could be construed as a potential conflict of interest.

347

348 **AUTHOR CONTRIBUTIONS**

349 FAS, JGAC-R, AT-C, MSSA, GSP, OAM-F and AGC conceptualized and designed the
350 study. FAS, CLSC, JPM, UHSP, IVS, JSM, GLS, NDA, EMVM, CMMA and AGC recruited
351 all the individuals for the study and performed the experiments. FAS, JPM, MSSA, OAM-F
352 and AGC analyzed the data. FAS, MSSA, OAM-F and AGC wrote the manuscript. VP-M,
353 JGAC-R, AT-C, ACRV, GSP, FM-G, OAM-F and AGC revised the manuscript. All authors
354 read and approved the final version of the manuscript.

355

356 **FUNDING**

357 Financial support was provided in the form of grants from Fundação de Amparo à
358 Pesquisa do Estado do Amazonas (FAPEAM) (Pró-Estado Program #002/2008,
359 #007/2018 and #005/2019, PRODOC Program #003/2022; STARTUP PARA O SUS
360 Program #012/2022 and POSGRAD Program #002/2023), Fundação de Amparo à
361 Pesquisa do Estado de Minas Gerais (FAPEMIG) (APQ-00821-20 – PPSUS Program
362 #03/2020), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and
363 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (PROCAD-
364 Amazônia 2018 Program - #88881.200581/2018-01). FAS, CLSC, JPM, IVS and GLS
365 have fellowships from FAPEAM, FAPEMIG and CAPES (MSc students). JSM was
366 research fellow from CAPES (PhD student). UHSP have fellowships from FAPEAM
367 (scientific initiation student). JGAC-R, ACRV, MSSA, OAM-F and AGC are research
368 fellows from CNPq. OAM-F participated in the fellowship program supported by the
369 Universidade do Estado do Amazonas (PROVISIT N° 005/2023-PROPESP/UEA). The
370 funders had no role in study design, the decision to publish, or preparation of the
371 manuscript.

372

373 **REFERENCES**

- 374 1. Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1
375 Infection. *Front Microbiol.* 2012;3. doi:10.3389/fmicb.2012.00388
- 376 2. Roucoux DF, Murphy EL. The epidemiology and disease outcomes of human T-
377 lymphotropic virus type II. *AIDS Rev.* 2004;6: 144–54.
- 378 3. Mahieux R, Gessain A. HTLV-3/STLV-3 and HTLV-4 Viruses: Discovery,
379 Epidemiology, Serology and Molecular Aspects. *Viruses.* 2011;3: 1074–1090.
380 doi:10.3390/v3071074
- 381 4. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Blayney D,
382 Golde D, et al. A New Subtype of Human T-Cell Leukemia Virus (HTLV-II)
383 Associated with a T-Cell Variant of Hairy Cell Leukemia. *Science* (1979). 1982;218:
384 571–573. doi:10.1126/science.6981847
- 385 5. Uchiyama T. HUMAN T CELL LEUKEMIA VIRUS TYPE I (HTLV-I) AND HUMAN
386 DISEASES. *Annu Rev Immunol.* 1997;15: 15–37.
387 doi:10.1146/annurev.immunol.15.1.15
- 388 6. Castro-Costa CM De, Araújo AQC, Barreto MM, Takayanagui OM, Sohler MP, Silva
389 ELM Da, et al. Proposal for Diagnostic Criteria of Tropical Spastic
390 Paraparesis/HTLV-I-Associated Myelopathy (TSP/HAM). *AIDS Res Hum*
391 *Retroviruses.* 2006;22: 931–935. doi:10.1089/aid.2006.22.931

- 392 7. Martinez MP, Al-Saleem J, Green PL. Comparative virology of HTLV-1 and HTLV-
393 2. *Retrovirology*. 2019;16: 21. doi:10.1186/s12977-019-0483-0
- 394 8. Takatani M, Crispim ME, Fraiji N, Stefani MMA, Kiesslich D. Clinical and laboratory
395 features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated
396 myelopathy/tropical spastic paraparesis from the Brazilian Amazon. *Rev Inst Med*
397 *Trop Sao Paulo*. 2017;59. doi:10.1590/s1678-9946201759005
- 398 9. Blanco S, Barile ME, Frutos MC, Vicente ACP, Gallego SV. Neurodegenerative
399 disease in association with sexual transmission of human T-cell lymphotropic virus
400 type 2 subtype b in Argentina. *Trans R Soc Trop Med Hyg*. 2022;116: 622–627.
401 doi:10.1093/trstmh/trab173
- 402 10. Vallinoto ACR, Gonçalves JSS, Abreu IN, de Oliveira Freitas V, Lima CNC, Botelho
403 BS, et al. Unique evidence of atypical lymphocytes and flower cells in indigenous
404 Xikrin do Bacajá people infected with HTLV-2. *Journal of Clinical Virology Plus*.
405 2023;3: 100155. doi:10.1016/j.jcvp.2023.100155
- 406 11. Gross C, Thoma-Kress AK. Molecular mechanisms of HTLV-1 cell-to-cell
407 transmission. *Viruses*. 2016. doi:10.3390/v8030074
- 408 12. Igakura T, Stinchcombe JC, Goon PKC, Taylor GP, Weber JN, Griffiths GM, et al.
409 Spread of HTLV-I Between Lymphocytes by Virus-Induced Polarization of the
410 Cytoskeleton. *Science* (1979). 2003;299: 1713–1716.
411 doi:10.1126/science.1080115
- 412 13. Verdonck K, González E, Van Dooren S, Vandamme A-M, Vanham G, Gotuzzo E.
413 Human T-lymphotropic virus 1: recent knowledge about an ancient infection. *Lancet*
414 *Infect Dis*. 2007;7: 266–281. doi:10.1016/S1473-3099(07)70081-6
- 415 14. Willems L, Hasegawa H, Accolla R, Bangham C, Bazarbachi A, Bertazzoni U, et al.
416 Reducing the global burden of HTLV-1 infection: An agenda for research and
417 action. *Antiviral Res*. 2017;137: 41–48. doi:10.1016/j.antiviral.2016.10.015
- 418 15. Beilke MA. Retroviral Coinfections: HIV and HTLV: Taking Stock of More Than a
419 Quarter Century of Research. *AIDS Res Hum Retroviruses*. 2012;28: 139–147.
420 doi:10.1089/aid.2011.0342
- 421 16. Kitagawa T. Antibodies to HTLV-I in Japanese Immigrants in Brazil. *JAMA: The*
422 *Journal of the American Medical Association*. 1986;256: 2342.
423 doi:10.1001/jama.1986.03380170058009
- 424 17. Catalan-Soares BC, Proietti FA, Carneiro-Proietti AB de F. Os vírus linfotrópicos
425 de células T humanos (HTLV) na última década (1990-2000): aspectos
426 epidemiológicos. *Revista Brasileira de Epidemiologia*. 2001;4: 81–95.
427 doi:10.1590/S1415-790X2001000200003
- 428 18. Carneiro-Proietti ABF, Ribas JGR, Catalan-Soares BC, Martins ML, Brito-Melo
429 GEA, Martins-Filho OA, et al. Infecção e doença pelos vírus linfotrópicos humanos
430 de células T (HTLV-I/II) no Brasil. *Rev Soc Bras Med Trop*. 2002;35: 499–508.
431 doi:10.1590/S0037-86822002000500013

- 432 19. Galvao-Castro B, Loures L, Rodrigues L, Sereno A, Ferreira Junior O, Franco L, et
433 al. Distribution of human T-lymphotropic virus type I among blood donors: a
434 nationwide Brazilian study. *Transfusion* (Paris). 1997;37: 242–243.
435 doi:10.1046/j.1537-2995.1997.37297203532.x
- 436 20. Morais MPE de, Gato CM, Maciel LA, Lalwani P, Costa CA, Lalwani JDB.
437 Prevalence of Human T-lymphotropic virus type 1 and 2 among blood donors in
438 Manaus, Amazonas State, Brazil. *Rev Inst Med Trop Sao Paulo*. 2017;59.
439 doi:10.1590/s1678-9946201759080
- 440 21. Catalan-Soares B, Carneiro-Proietti AB de F, Proietti FA. Heterogeneous
441 geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II):
442 serological screening prevalence rates in blood donors from large urban areas in
443 Brazil. *Cad Saude Publica*. 2005;21: 926–931. doi:10.1590/S0102-
444 311X2005000300027
- 445 22. Rosadas C, Brites C, Arakaki-Sánchez D, Casseb J, Ishak R. Protocolo Brasileiro
446 para Infecções Sexualmente Transmissíveis 2020: infecção pelo vírus linfotrópico
447 de células T humanas (HTLV). *Epidemiologia e Serviços de Saúde*. 2021;30.
448 doi:10.1590/s1679-497420200006000015.esp1
- 449 23. Moreno C, Balangero M, Barbás MG, Cudolá A, Gallego S. Diagnóstico serológico
450 de HTLV-1/2: combinación de técnicas de tamizaje para definir el estatus
451 serológico en donantes de sangre. *Rev Argent Microbiol*. 2013;45: 165–168.
452 doi:10.1016/S0325-7541(13)70019-1
- 453 24. Coelho-dos-Reis JGA, Martins-Filho OA, de Brito-Melo GEA, Gallego S, Carneiro-
454 Proietti AB, Souza JG, et al. Performance of IgG and IgG1 anti-HTLV-1 reactivity
455 by an indirect immunofluorescence flow cytometric assay for the identification of
456 persons infected with HTLV-1, asymptomatic carriers and patients with myelopathy.
457 *J Virol Methods*. 2009;160: 138–148. doi:10.1016/j.jviromet.2009.05.007
- 458 25. Pimenta de Paiva L, Coelho-dos-Reis JGA, Trindade BC, Peruhype-Magalhães V,
459 Silva Araújo MS, Gonçalves JJ, et al. A New Flow Cytometry-Based Single Platform
460 for Universal and Differential Serodiagnosis of HTLV-1/2 Infection. *Front Immunol*.
461 2022;13. doi:10.3389/fimmu.2022.795815
- 462 26. Coelho-dos-Reis JG, Peruhype-Magalhães V, Pascoal-Xavier MA, de Souza
463 Gomes M, do Amaral LR, Cardoso LM, et al. Flow cytometric-based protocols for
464 assessing anti-MT-2 IgG1 reactivity: High-dimensional data handling to define
465 predictors for clinical follow-up of Human T-cell Leukemia virus type-1 infection. *J*
466 *Immunol Methods*. 2017;444: 36–46. doi:10.1016/j.jim.2017.02.006
- 467 27. Martins ML, Santos AC da S, Namen-Lopes MS, Barbosa-Stancioli EF, Utsch DG,
468 Carneiro-Proietti AB de F. Long-term serological follow-up of blood donors with an
469 HTLV-Indeterminate Western Blot: Antibody Profile of Seroconverters and
470 Individuals With False Reactions. *J Med Virol*. 2010;82: 1746–1753.
471 doi:10.1002/jmv.21881
- 472 28. Namen-Lopes MSS, Martins ML, Drummond PC, Lobato RR, Carneiro-Proietti
473 ABF. Lookback study of HTLV-1 and 2 seropositive donors and their recipients in

- 474 Belo Horizonte, Brazil. *Transfusion Medicine*. 2009;19: 180–188.
475 doi:10.1111/j.1365-3148.2009.00932.x
- 476 29. Campos KR, Santos FLN, da Silva Brito V, Gonçalves NLS, Araujo THA, Galvão-
477 Castro B, et al. Line Immunoassay for Confirmation and Discrimination of Human
478 T-Cell Lymphotropic Virus Infections in Inconclusive Western Blot Serum Samples
479 from Brazil. *J Clin Microbiol*. 2019;58. doi:10.1128/JCM.01384-19
- 480 30. Kiely P, Walker K, Parker S, Cheng A. Analysis of sample-to-cutoff ratios on
481 chemiluminescent immunoassays used for blood donor screening highlights the
482 need for serologic confirmatory testing. *Transfusion (Paris)*. 2010;50: 1344–1351.
483 doi:10.1111/j.1537-2995.2009.02572.x
- 484 31. Tosswill JHC, Taylor GP. Interpretation of low reactivity in the Abbott Architect
485 rHTLV I/II assay. *Transfusion Medicine*. 2018;28: 326–330. doi:10.1111/tme.12482
- 486 32. Yun SG, Kim S, Sohn JY, Cho Y. Evaluation of Elecsys HTLV-I/II assay in
487 comparison with ARCHITECT rHTLV-I/II assay with Korean samples. *J Clin Lab
488 Anal*. 2019;33. doi:10.1002/jcla.22909
- 489 33. da Motta Passos LN, de Moraes MPE, Tamegão-Lopes B, de Lemos JAR, de Lima
490 Machado PR, Mira MT, et al. Absence of HTLV-1/2 infection and dermatological
491 diseases in Manaus, State of Amazonas, Brazil. *Rev Soc Bras Med Trop*. 2014;47:
492 507–509. doi:10.1590/0037-8682-0196-2013
- 493 34. Catalan-Soares B, Carneiro-Proietti AB de F, Proietti FA. Heterogeneous
494 geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II):
495 serological screening prevalence rates in blood donors from large urban areas in
496 Brazil. *Cad Saude Publica*. 2005;21: 926–931. doi:10.1590/S0102-
497 311X2005000300027
- 498 35. Ishak R, de Oliveira Guimarães Ishak M, Vallinoto ACR. The challenge of
499 describing the epidemiology of HTLV in the Amazon region of Brazil. *Retrovirology*.
500 2020;17: 4. doi:10.1186/s12977-020-0512-z
- 501 36. Guiraud V, Crémoux F, Leroy I, Cohier J, Hernandez P, Mansaly S, et al.
502 Comparison of two new HTLV-I/II screening methods, Abbott Alinity i rHTLV-I/II and
503 Diasorin LIAISON® XL murex recHTLV-I/II, to Abbott architect rHTLV-I/II assay.
504 *Journal of Clinical Virology*. 2023;164: 105446. doi:10.1016/j.jcv.2023.105446
- 505 37. Hayes CG, Burans JP, Oberst RB. Antibodies to Human T Lymphotropic Virus Type
506 I in a Population from the Philippines: Evidence for Cross-Reactivity with
507 *Plasmodium falciparum*. *Journal of Infectious Diseases*. 1991;163: 257–262.
508 doi:10.1093/infdis/163.2.257
- 509 38. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. *Boletim
510 Epidemiológico*. 2015;46: 1–5. doi:10.1590/S1415-790X2004000400010
- 511 39. Seed CR, Margaritis AR, Bolton W V., Kiely P, Parker S, Piscitelli L. Improved
512 efficiency of national HIV, HCV, and HTLV antibody testing algorithms based on
513 sequential screening immunoassays. *Transfusion (Paris)*. 2003;43: 226–234.
514 doi:10.1046/j.1537-2995.2003.00304.x

- 515 40. Kiely P, Walker K, Parker S, Cheng A. Analysis of sample-to-cutoff ratios on
516 chemiluminescent immunoassays used for blood donor screening highlights the
517 need for serologic confirmatory testing. *Transfusion (Paris)*. 2010;50: 1344–1351.
518 doi:10.1111/j.1537-2995.2009.02572.x
- 519 41. Vo MT, Bruhn R, Kaidarova Z, Custer BS, Murphy EL, Bloch EM. A retrospective
520 analysis of false-positive infectious screening results in blood donors. *Transfusion*
521 (Paris). 2016;56: 457–465. doi:10.1111/trf.13381

522

523 **FIGURE CAPTIONS**

524 **Figure 1. Seroprevalence for anti-HTLV antibodies in candidates for blood**
525 **donations at the Amazonas State Blood Center. a)** Anti-HTLV reactivity profile of 409
526 candidates for blood donations using CLIA during screening (2018 – 2022). CLIA results
527 of 151 candidates for blood donations at retesting (2023). **b)** Correlation analysis between
528 CLIA RLU values during screening and retesting. *CLIA: chemiluminescence assay; RLU:*
529 *relative light units.*


530 **Figure 2. Performance of different immunological assays to detect anti-HTLV**
531 **antibodies. a)** CLIA results were classified as low, intermediate or high based on the
532 RLU values; the western blot results were categorized as negative, indeterminate or
533 positive, according to band profile, and FC-Simplex results were defined as negative or
534 positive, according to the PPFC values. **b)** Comparison of CLIA vs WB, CLIA vs FC-
535 Simplex and WB vs FC-Simplex results. *CLIA: chemiluminescence assay; RLU: relative*
536 *light units; WB: western blot assay; PPFC: percentage of positive fluorescent cells.*

537 **Figure 3. Differential diagnosis of HTLV-1/2 infection after retesting using the FC-**
538 **Duplex IgG1. a)** Anti- MT-2 (1:32) and anti- MoT (1:32) reactivity used to define the
539 HTLV-1 and HTLV-2 diagnosis according to criterion 1, previously proposed by Pimenta
540 de Paiva et al. [25]. **b)** Agreement between FC-Duplex HTLV-1/2 IgG1 and western blot
541 results. *PPFC: percentage of positive fluorescent cells; WB: western blot assay.*

542 **Supplementary Figure 1. Differential diagnosis of HTLV-1/2 infection after retesting**
543 **using the FC-Duplex IgG1. a)** Anti-MT-2 (1:32) and anti-MoT (1:1,024) reactivity used
544 to define the HTLV-1 and HTLV-2 diagnosis according to criterion 1, previously proposed
545 by Pimenta de Paiva et al. [25]. **b)** Agreement between FC-Duplex HTLV-1/2 IgG1 and
546 western blot results. *PPFC: percentage of positive fluorescent cells; WB: western blot*
547 *assay*

548 **Supplementary Figure 2. Differential diagnosis of HTLV-1/2 infection after retesting**
549 **using the FC-Duplex IgG1. a)** Anti- MT-2 (1:32) and anti-MoT (1:2,048) reactivity used
550 to define the HTLV-1 and HTLV-2 diagnosis according to criterion 1, previously proposed
551 by Pimenta de Paiva et al. [25]. **b)** Agreement between FC-Duplex HTLV-1/2 IgG1 and
552 western blot results. *PPFC: percentage of positive fluorescent cells; WB: western blot*
553 *assay.*

a)



b)





Figure 1

Figure 1

a)

Anti-HTLV Immunological Assays at Retesting (2023)



b)





Figure 2

Figure 2



b) Western Blot vs FC-Duplex IgG1 - (2023)




Figure 3

Figure 3